CINCINNATI, Ohio, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Triplefin, an industry leader providing pharmaceutical marketing support solutions including patient reimbursement support services; patient assistance programs; traditional and alternative Rx sampling; and patient adherence solutions, announced today it has earned a spot on the Deloitte Cincinnati USA 100 list for the fifth consecutive year.
Accounting and consulting firm Deloitte ranked companies by their annual sales revenue, as well as required each firm to complete an in-depth survey, to arrive at the 100 largest, privately held companies in Greater Cincinnati and Northern Kentucky. This year's survey included questions about fiscal projections, hiring and technology, as well as views on the direction of the national and local economies. More than 400 firms were considered for this honor, with Triplefin winning out the number 36th position, up from 49th in 2011.
"Earning this achievement five years in a row is a testament to Triplefin's unyielding commitment to the highest level of service, along with our patient-centric focus on customized solutions. We are successfully removing barriers to Rx brand access and adherence and connecting more patients, physicians, and payers to pharmaceutical brands as we continue to expand our breadth of services," said CEO Greg LaLonde.
Triplefin is recognized as the premier provider of pharmaceutical marketing support solutions. For more than 30 years, Triplefin has continually helped pharmaceutical brand managers remove barriers to brand access and adherence and put prescription brands into patients' hands…and keep them there throughout treatment. Today, more than 40 pharmaceutical manufacturing companies (including 13 of the top 20), representing more than 150 brands across multiple therapeutic categories, have connected with Triplefin and experienced the success of Triplefin Solutions.
About Triplefin
Triplefin, founded in 1981, is privately owned and headquartered in Cincinnati, Ohio. Triplefin provides strategic, customized brand support and growth solutions to leading pharmaceutical manufacturing companies. Our mission is to connect patients, providers, pharmacies, and payers to improve outcomes and to remove brand challenges with access, acquisition, and adherence.
A highly experienced team with an in-depth understanding of the pharmaceutical marketing industry is standing by to help brand managers grow their brands. For more information about Triplefin's Solutions, please visit www.triplefin.com or connect with LeTicia Hallstead, Executive Vice President, Business Development at 855-TRPLFIN (855-877-5346).
The Triplefin logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=15178